BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALSPRNewsWire • 11/10/22
BrainStorm Cell Therapeutics to Announce Third Quarter Results and Provide a Corporate UpdatePRNewsWire • 11/07/22
BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS MeetingPRNewsWire • 11/07/22
BrainStorm Cell Therapeutics Presents NurOwn® Phase 2 Progressive MS Biomarker Data at the 38th ECTRIMS CongressPRNewsWire • 10/20/22
BrainStorm Presents New Biomarker Analyses from NurOwn's Phase 3 ALS Trial at the ALS ONE Research SymposiumPRNewsWire • 10/07/22
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn® Phase 2 Progressive MS Trial in Multiple Sclerosis JournalPRNewsWire • 09/15/22
Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/15/22
BrainStorm Cell Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Corporate UpdatePRNewsWire • 08/15/22
Brainstorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/16/22
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results and Provides a Corporate UpdatePRNewsWire • 05/16/22
BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco MeetingPRNewsWire • 05/04/22
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate UpdatePRNewsWire • 05/02/22
BrainStorm Cell Therapeutics Inc. (BCLI) CEO Chaim Lebovits on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/28/22
Brainstorm Cell Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m.PRNewsWire • 03/28/22
BrainStorm Cell Therapeutics Announces Full Year 2021 Financial Results and Provides a Corporate UpdatePRNewsWire • 03/28/22
BrainStorm to Announce Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate UpdatePRNewsWire • 03/14/22
BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific ConferencePRNewsWire • 02/28/22
Brainstorm Cell Therapeutics Announces Grant of a New Brazilian Patent Covering Methods of Manufacturing NurOwn®PRNewsWire • 02/15/22
BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS Research SummitPRNewsWire • 01/27/22